Dr. Michael J. Castine III, MD
Medical Oncology (Medical Oncology Physician)
8595 Picardy Ave, Suite 400
Baton Rouge, LA 70809
Who else practices at this address →
East Baton Rouge Parish includes primary care (46% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 577
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Louisiana State University School of Medicine in New Orleans
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
LA license 12998R
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus St Frances Cabrini Hospital Alexandria, LA
- Baton Rouge General Medical Center Baton Rouge, LA
- Rapides Regional Medical Center Alexandria, LA
- Lane Regional Medical Center Zachary, LA
- West Feliciana PArish Hospital Saint Francisville, LA
Medical groups
- American Oncology PArtners PA (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 577
- Services billed
- 204,500
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 21,420 | 20 |
| Injection, aprepitant, 1 mg | 15,990 | 33 |
| Injection, paclitaxel, 1 mg | 6,129 | 12 |
| Injection, denosumab, 1 mg | 3,600 | 14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,768 | 59 |
| Injection, ferric derisomaltose, 10 mg | 2,100 | 19 |
| Injection, palonosetron hcl, 25 mcg | 1,670 | 44 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,452 | 419 |
| Injection, ondansetron hydrochloride, per 1 mg | 1,320 | 27 |
| Established patient office or other outpatient visit, 30-39 minutes | 752 | 266 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Baton Rouge, LA | 203 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Baton Rouge, LA | 164 |
| Prednisone Other prescribers in Baton Rouge, LA | 108 |
| Revlimid (lenalidomide) | 94 |
| Ondansetron Hcl Other prescribers in Baton Rouge, LA | 88 |
| Hydroxyurea Other prescribers in Baton Rouge, LA | 82 |
| Levothyroxine Sodium Other prescribers in Baton Rouge, LA | 75 |
| Dexamethasone Other prescribers in Baton Rouge, LA | 74 |
| Venclexta (venetoclax) | 71 |
| Gabapentin Other prescribers in Baton Rouge, LA | 68 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 40 companies reported 144 payments worth $3,260 in total to this clinician.
| Janssen Biotech, Inc. | $385 |
|---|---|
| Pfizer Inc. | $242 |
| Daiichi Sankyo Inc. | $234 |
| Novartis Pharmaceuticals Corporation | $197 |
| AbbVie Inc. | $166 |
| Genzyme Corporation | $158 |
| GlaxoSmithKline, LLC. | $121 |
| AstraZeneca Pharmaceuticals LP | $117 |
| Food and Beverage | $2,960 |
|---|---|
| Education | $299 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Mar 24, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.95 |
| Daiichi Sankyo Inc. Nov 10, 2025 | Education Enhertu · ONCOLOGY · in-kind | $99.00 |
| Sanofi-aventis U.S. LLC Apr 17, 2025 | Education SARCLISA · Oncology · in-kind | $89.99 |
| Pfizer Inc. Mar 31, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $10.54 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $179,245 in research payments for these studies, mostly to the institutions running them.
- Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie Inc. · Active, not recruiting · NCT04401748 - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958 - M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie Inc. - A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Eli Lilly and Company · Recruiting · NCT05254743 - SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negativ…
AstraZeneca Pharmaceuticals LP - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Ipsen Bioscience Inc. · Completed · NCT04083235 - A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast …
Novartis Pharmaceuticals Corporation - A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia i…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.